Aerovate Therapeutics, Inc.
AVTE
$0.06
Change (1 day)
$32.42
Year High
$1.25
Year Low
Categories
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
P/E ratio for Aerovate Therapeutics, Inc. (AVTE)
P/E ratio as of 2023: -7.89
According to Aerovate Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.89. At the end of 2022 the company had a P/E ratio of -13.92.
P/E ratio history for Aerovate Therapeutics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.89 |
| 2022 | -13.92 |
| 2021 | -12.53 |
| 2020 | -61.65 |
| 2019 | -167.35 |